1 / 8

Cancer Proteomics Group

Cancer Proteomics Group . Prof. Richard Christopherson.

gordon
Télécharger la présentation

Cancer Proteomics Group

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cancer Proteomics Group Prof. Richard Christopherson

  2. Left-right: Dr Larissa Belov, Prof Richard Christopherson, Dr Ben Crossett (SUPRU), MuntherAlomari (PhD), Duthika Mallawaaratchy (PhD), Jerry Zhou (PhD), Kieran Matic (Honours), YipingChe (PhD), Dr Kim Kaufman, Trisha Almazi (PhD) Missing: Dr Swetlana Mactier, Erin Sykes (PhD).

  3. Cancers we study: • Colorectal cancer (CRC) • Leukaemia • Melanoma • Glioblastoma (GBM)

  4. Anti-cancer drugs • Identification of proteome changes in cancer cells after treatment with a drug such as: • Purine analogues (e.g., fludarabine) • HSP90 inhibitors (e.g., SNX-7081) • ER-stress inducers (e.g., thapsigargin) • Understand mechanisms of drug action and resistance, identification of new drug targets

  5. Cell surface markers • DotScan™ CD antibody microarrays • Capture live cells and obtain a surface profile (disease signature, immunophenotype) • In collaboration with major NSW hospitals, we have collected and tested many different clinical samples, including: • Leukaemias • Colorectal cancers • Metastatic melanoma • To improve disease stratification, prognostication and prediction of response to treatment

  6. Comprehensive, quantitative clinical proteomics • Stage III melanoma Survival analyses – prognostic biomarkers good versus poor prognosis groups with identical stage cancers • Glioblastoma multiforme Serial lesions, pre and post chemotherapy, biomarkers for chemo-resistance • Chronic lymphocytic Leukaemia Stable vsprogressive disease course

  7. Techniques • Clinical samples and cell lines • In vitro chemotherapy treatment • Flow cytometry • Sub-cellular proteome isolation • Cytosol, nucleus, mitochondria and plasma membrane • Mass Spectrometry and gel-based analyses (SUPRU) • Quantitative analysis • DIGE, iTRAQ, SRM and label-free methods

  8. Thank you! Christopherson lab

More Related